Omran 2016.
Study characteristics | |||
Patient Sampling | A total of 88 consecutive Egyptian individuals attending the Tropical Medicine Department, Mansoura University hospitals, Mansoura, Egypt during the period from May 2012 to April 2013 were enrolled in this study. They were classified into 3 groups. The first group included 53 patients with hepatocellular carcinoma (HCC), the second group included 20 patients with liver cirrhosis, and the third group of 15 apparently healthy participants serving as control group were included. Patients with heart failure, kidney failure, rheumatoid arthritis, autoimmune liver diseases, hepatitis B virus, metabolic disorders, or other malignancies were excluded. Age range: 42‐70. Males 71% |
||
Patient characteristics and setting | |||
Index tests | AFP: the level of serum alpha fetoprotein was estimated by chemiluminescence, with IMMULITE (1000) AFP kit (Diagnostic Products Corporation; Los Angeles, CA, USA). AFP cut‐off value 400 ng/mL | ||
Target condition and reference standard(s) | HCC: the diagnosis of HCC was done according to American Association for the Study of Liver Diseases (AASLD) practice guidelines. | ||
Flow and timing | No information on interval between index test and reference standard | ||
Comparative | |||
Notes | No information on conflicts of interest | ||
Methodological quality | |||
Item | Authors' judgement | Risk of bias | Applicability concerns |
DOMAIN 1: Patient Selection | |||
Was a consecutive or random sample of patients enrolled? | Yes | ||
Was a case‐control design avoided? | No | ||
Did the study avoid inappropriate exclusions? | No | ||
Could the selection of patients have introduced bias? | High risk | ||
Are there concerns that the included patients and setting do not match the review question? | High | ||
DOMAIN 2: Index Test (AFP) | |||
Were the index test results interpreted without knowledge of the results of the reference standard? | No | ||
If a threshold was used, was it pre‐specified? | Yes | ||
Could the conduct or interpretation of the index test have introduced bias? | High risk | ||
Are there concerns that the index test, its conduct, or interpretation differ from the review question? | Low concern | ||
DOMAIN 2: Index Test (US+AFP) | |||
DOMAIN 2: Index Test (US) | |||
DOMAIN 3: Reference Standard | |||
Is the reference standards likely to correctly classify the target condition? | No | ||
Were the reference standard results interpreted without knowledge of the results of the index tests? | Yes | ||
Could the reference standard, its conduct, or its interpretation have introduced bias? | High risk | ||
Are there concerns that the target condition as defined by the reference standard does not match the question? | Low concern | ||
DOMAIN 4: Flow and Timing | |||
Was there an appropriate interval between index test and reference standard? | Unclear | ||
Did all patients receive the same reference standard? | No | ||
Were all patients included in the analysis? | Yes | ||
Could the patient flow have introduced bias? | High risk |